



**RESPONSE UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE  
EXAMINING GROUP 1648**

**PATENT**  
Attorney Docket No. 175912

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Boyd

Application No. 09/427,873

Filed: October 27, 1999

For: METHOD OF USING  
CYANOVIRINS TO INHIBIT  
VIRAL INFECTION

Art Unit: 1648

Examiner: J. Parkin

**RECEIVED**  
FEB 05 2002  
TECH CENTER 1600/2900

**PENDING CLAIMS AFTER  
OFFICE ACTION DATED NOVEMBER 6, 2001**

20. A method of inhibiting therapeutically or prophylactically a viral infection of a host, which method comprises administering to the host an antiviral effective amount of an isolated and purified antiviral agent selected from the group consisting of an antiviral protein, an antiviral peptide, an antiviral protein conjugate, and an antiviral peptide conjugate, wherein said antiviral protein or antiviral peptide has an amino acid sequence of SEQ ID NO: 2 or a mutant thereof, whereupon administration of said antiviral effective amount of said antiviral agent, said viral infection of said host is inhibited.

21. The method of claim 20, wherein said antiviral protein comprises the amino acid sequence of SEQ ID NO: 2.

22. The method of claim 20, wherein said antiviral protein conjugate or said antiviral peptide conjugate comprises (i) an amino acid sequence of SEQ ID NO: 2 or a mutant thereof, and (ii) an isolated and purified viral envelope glycoprotein.

23. The method of claim 22, wherein said antiviral protein comprises the amino acid sequence of SEQ ID NO: 2.

24. The method of claim 22, wherein said isolated and purified viral envelope glycoprotein is an isolated and purified retroviral envelope glycoprotein.

25. The method of claim 24, wherein said isolated and purified retroviral envelope glycoprotein is an isolated and purified immunodeficiency viral envelope glycoprotein.

26. The method of claim 25, wherein said isolated and purified immunodeficiency viral envelope glycoprotein is an isolated and purified viral envelope glycoprotein of HIV-1 or HIV-2.

27. The method of claim 26, wherein said isolated and purified viral envelope glycoprotein of HIV-1 or HIV-2 comprises gp120.